What Can You Give a Child for Conjunctivitis?
Title: What Can You Give a Child for Conjunctivitis?Category: Diseases and ConditionsCreated: 4/5/2022 12:00:00 AMLast Editorial Review: 4/5/2022 12:00:00 AM (Source: MedicineNet Kids Health General)
Source: MedicineNet Kids Health General - April 5, 2022 Category: Pediatrics Source Type: news

Conjunctivitis in Moderate-to-severe Atopic Dermatitis Conjunctivitis in Moderate-to-severe Atopic Dermatitis
Are patients receiving tralokinumab for moderate-to-severe atopic dermatitis at increased risk of developing conjunctivitis?The British Journal of Dermatology (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - April 4, 2022 Category: Allergy & Immunology Tags: Dermatology Journal Article Source Type: news

Pink eye: Three common sensations felt in the eyes warning of conjunctivitis
PINK eye or conjunctivitis is highly treatable and preventable. Unless your case of pink is severe, pink eye can heal on its own without treatment. How can you know for sure you may be at risk of the condition? (Source: Daily Express - Health)
Source: Daily Express - Health - February 1, 2022 Category: Consumer Health News Source Type: news

How Long Does It Take for Allergic Conjunctivitis to Go Away?
Title: How Long Does It Take for Allergic Conjunctivitis to Go Away?Category: Diseases and ConditionsCreated: 1/13/2022 12:00:00 AMLast Editorial Review: 1/13/2022 12:00:00 AM (Source: MedicineNet Eyesight General)
Source: MedicineNet Eyesight General - January 13, 2022 Category: Opthalmology Source Type: news

Is Allergic Conjunctivitis the Same as Conjunctivitis?
Title: Is Allergic Conjunctivitis the Same as Conjunctivitis?Category: Diseases and ConditionsCreated: 1/13/2022 12:00:00 AMLast Editorial Review: 1/13/2022 12:00:00 AM (Source: MedicineNet Eyesight General)
Source: MedicineNet Eyesight General - January 13, 2022 Category: Opthalmology Source Type: news

How Do I Know if I Have Bacterial or Viral Conjunctivitis?
Title: How Do I Know if I Have Bacterial or Viral Conjunctivitis?Category: Diseases and ConditionsCreated: 1/12/2022 12:00:00 AMLast Editorial Review: 1/12/2022 12:00:00 AM (Source: MedicineNet Eyesight General)
Source: MedicineNet Eyesight General - January 12, 2022 Category: Opthalmology Source Type: news

Coronavirus update: New report finds two warning signs of COVID-19 on your face
AROUND one in six people will have complications from COVID-19, including some that are life-threatening. Some common complications include acute respiratory failure, pneumonia and acute liver injury. A new report suggests ocular complications, including conjunctivitis and sinusitis, may also be a manifestation of COVID-19. (Source: Daily Express - Health)
Source: Daily Express - Health - July 31, 2021 Category: Consumer Health News Source Type: news

Study Estimates Incidence of Dupilumab-Related Conjunctivitis Study Estimates Incidence of Dupilumab-Related Conjunctivitis
The overall incidence rate of conjunctivitis within 6 months of starting treatment was 6.6% in dupilumab users, compared with 3.3% in methotrexate users.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - June 18, 2021 Category: Drugs & Pharmacology Tags: Dermatology News Source Type: news

Allergic Conjunctivitis Severely Affects Children's Quality of Life Allergic Conjunctivitis Severely Affects Children's Quality of Life
Physical, emotional, social, and especially school functioning were all affected. Parents also experienced large effects on quality of life.Medscape Medical News (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - June 15, 2021 Category: Opthalmology Tags: Ophthalmology News Source Type: news

U.S. FDA Approves ALK's Ragwitek (Short Ragweed Pollen Allergen Extract) Tablet for Sublingual Use as Immunotherapy for Children and Adolescents With Short Ragweed Pollen-Induced Allergic Rhinitis With or Without Conjunctivitis
ROUND ROCK, Texas, April 19, 2021 /PRNewswire/ -- ALK (ALKB: DC / OMX: ALK B / AKABY / AKBLF), a global, research-driven pharmaceutical company that focuses on the diagnosis and treatment of allergies, announced that the U.S. Food and Drug... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - April 19, 2021 Category: Drugs & Pharmacology Source Type: news

From pink eye to muffled hearing, some unusual COVID -19 symptoms being observed
Some unusual symptoms include conjunctivitis (pink eye), hearing loss with symptoms such as muffled hearing, reduced hearing, ear pain and gastrointestinal disorders. (Source: The Economic Times)
Source: The Economic Times - April 19, 2021 Category: Consumer Health News Source Type: news

Reducing suspicion of sexual abuse in paediatric chlamydial conjunctivitis using ompA genotyping - Mitchell A, Patel M, Manning C, Abbott J.
Chlamydia trachomatis is a Gram-negative bacterium that causes urogenital tract infections, and ocular infections including trachoma, neonatal conjunctivitis and adult chlamydial inclusion conjunctivitis. A positive C. trachomatis diagnosis in children oft... (Source: SafetyLit)
Source: SafetyLit - April 4, 2021 Category: International Medicine & Public Health Tags: Age: Infants and Children Source Type: news

Pink Eye (Conjunctivitis): Types, Treatment, and Symptoms
Title: Pink Eye (Conjunctivitis): Types, Treatment, and SymptomsCategory: Diseases and ConditionsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 3/26/2021 12:00:00 AM (Source: MedicineNet Eyesight General)
Source: MedicineNet Eyesight General - March 26, 2021 Category: Opthalmology Source Type: news

Vivimed Labs gets approval from Uzbekistan govt for two products
The company has received approval for Bilastin tablets, which are used for the treatment of allergic Rhino conjunctivitis and Urticaria, the Hyderabad-based company said in a regulatory filing. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - March 8, 2021 Category: Pharmaceuticals Source Type: news

Janssen Announces U.S. FDA Approval of CABENUVA (rilpivirine and cabotegravir), the First Long-Acting Regimen for the Treatment of HIV
TITUSVILLE, N.J., January 21, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved CABENUVA (consisting of Janssen’s rilpivirine and ViiV Healthcare’s cabotegravir), the first and only once-monthly, long-acting regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults. The novel regimen was co-developed as part of a collaboration with ViiV Healthcare and builds on Janssen’s 25-year commitment to make HIV history. In the U.S., ViiV Healthcare is the marketing authorization holder for CABENUVA.C...
Source: Johnson and Johnson - January 22, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news